41303-45-1

Basic information

• Product Name: 6,7-(METHYLENEDIOXY)-1-TETRALONE
• Synonyms: 6,7-(METHYLENEDIOXY)-1-TETRALONE
• CAS NO: 41303-45-1
• Molecular Formula: C₁₁H₁₀O₃
• Molecular Weight: 190.2
• Mol File: 41303-45-1.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6,7-(METHYLENEDIOXY)-1-TETRALONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-(METHYLENEDIOXY)-1-TETRALONE(41303-45-1)
• EPA Substance Registry System: 6,7-(METHYLENEDIOXY)-1-TETRALONE(41303-45-1)

Safety Data

• Hazardous Substances Data: 41303-45-1(Hazardous Substances Data)

Usage

General Description

6,7-(Methylenedioxy)-1-tetralone is a chemical compound with the molecular formula C11H10O3. It is a member of the tetralone family and is structurally related to the psychoactive drug MDA. 6,7-(METHYLENEDIOXY)-1-TETRALONE is known for its potential psychoactive effects and is sometimes used in the production of recreational drugs. It is also known to have antioxidant and neuroprotective properties. 6,7-(Methylenedioxy)-1-tetralone is a versatile chemical with various potential applications in the fields of pharmacology and medicine.

Upstream product

• 77814-40-5 4-Benzo[1,3]dioxol-5-yl-butyryl azide 
• 98799-42-9 4-<3,4-(methylenedioxy)phenyl>butanoic acid chloride 
• 54549-75-6 6,7-dihydroxy-3,4-dihydro-1(2H)-naphthalenone 
• 74-95-3 1,1-dibromomethane 
• 120-57-0 piperonal 
• 5333-34-6 3-(3,4-dimethoxybenzoyl)propionic acid 
• 91-16-7 1,2-dimethoxybenzene 
• 13575-74-1 4-(3,4-dimethoxyphenyl)butanoic acid 
• 7031-05-2 3-(3,4-methylenedioxyphenyl)propyl chloride 
• 7031-03-0 3-(benzo[d][1,3]dioxol-5-yl)propan-1-ol 
• 94-59-7 1-allyl-3,4-methylenedioxybenzene 
• 119030-60-3 4-(benzo[1,3]dioxol-5-yl)butyric acid methyl ester 
• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 
• 13575-75-2 6,7-dimethoxy-1-oxo-1,2,3,4-tetrahydronaphthalene 

Downstream Products

• 88284-60-0 6-(4-Benzhydryl-piperazin-1-ylmethyl)-7,8-dihydro-6H-naphtho[2,3-d][1,3]dioxol-5-one 
• 65341-21-1 N-(3,4-dihydro-6,7-methylenedioxy-1-naphthyl)-2,3,6-trimethoxy-N-methylbenzamide 
• 1359946-06-7 7-chloro-9-methoxy-5,6-dihydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-c]acridin-8-yl benzenesulfonate 
• 15575-49-2 6-acetonyldihydrochelerythrine 
• 34316-15-9 chelerythrinium 
• 18797-79-0 (+/-)-11-epicorynoline 
• 476-33-5 (+/-)-homochelidonine 
• 28342-33-8 oxychelerythrine 
• 213698-57-8 N-[6-(2,4,5-Trimethoxy-phenyl)-naphtho[2,3-d][1,3]dioxol-5-yl]-formamide 
• 180411-21-6 N-[6-(3,4-Dimethoxy-phenyl)-naphtho[2,3-d][1,3]dioxol-5-yl]-formamide 
• 105594-89-6 2-(3,4-dimethoxyphenyl)-6,7-methylenedioxy-1-(N-methylformamido)naphthalene 
• 13063-04-2 nitidine chloride 
• 6900-99-8 norchelerythrine 
• 18034-03-2 nornitidine 

Relevant articles and documents

NAPTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF

Provided herein are naphthoquinones compounds such as those with a hydrogen bond donating group of the formula (I): wherein: R1, R2, R3, R4, R5, and n are as defined herein. Also provided herein are pharmaceutical composition of the present compounds and methods of treatment using the compounds including their use in the treatment of cancer.

12-N-Methylated 5,6-dihydrobenzo[c]acridine derivatives: A new class of highly selective ligands for c-myc G-quadruplex DNA

12-N-Methylated and non-methylated 5,6-dihydrobenzo[c]acridine derivatives were designed and synthesized as new series of c-myc G-quadruplex binding ligands. Their interactions with c-myc G-quadruplex were evaluated using fluorescence resonance energy tra

Aminomethylcarboxylic acid derivatives

The present invention relates to aminomethylcarboxylic acid derivatives general formula (I), wherein Z is (CH2)n, O, S, SO, SO2or N—R5; n is 0, 1 or 2; X represents 1-3 substituents independently selected from hydrogen, halogen, (C1-6)alkyloxy, (C3-6)cycloalkyloxy, (C6-12)aryloxy, (C6-12)aryl, thienyl, SR6, SOR6, SO2R6, NR6R6, NHR6, NH2, NHCOR6, NSO2R6, CN, COOR6and (C1-4)alkyl, optionally substituted with halogen, (C6-12)aryl, (C1-6)alkyloxy or (C6-12)aryloxy; or 2 substituents at adjacent positions together represent a fused (C5-6)aryl group, a fused (C5-6)cycloalkyl ring or O—(CH2)m—O; m is 1 or 2; Y represents 1-3 substituents independently selected from hydrogen, halogen, (C1-4)alkyloxy, SR6, NR6R6and (C1-4)alkyl, optionally substituted with halogen; R1is COOR7or CONR8R9; R2and R6are (C1-4)alkyl; R3, R4and R5are independently hydrogen or (C1-4)alkyl; R7, R8and R9are independently hydrogen, (C1-4)alkyl, (C6-12)aryl or arylalkyl; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these aminomethylcarboxylic acid derivatives in therapy, more specifically for the treatment of CNS disorders.